Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

March 31, 2012

Conditions
Atopic Dermatitis
Interventions
DRUG

Fluzone® Intradermal (Sanofi Pasteur Inc.)

"Fluzone® Intradermal trivalent vaccine is a clear-to-slightly opalescent, preservative-free suspension containing formaldehyde-inactivated split influenza viruses for intradermal delivery of 0.1 mL via an ultra-fine micro-needle. The vaccine is supplied as a single-dose, in a latex-free, pre-filled microinjection system. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs.~Fluzone® Intradermal is standardized according to United States Public Health Service (US PHS) requirements and is formulated to contain HA of each of the following three influenza strains recommended for the 2011-2012 influenza season: A/California/07/2009 X-179A (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/60/2008-like virus."

Trial Locations (1)

80206

National Jewish Health, Denver

All Listed Sponsors
collaborator

Atopic Dermatitis Research Network

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01518478 - Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot | Biotech Hunter | Biotech Hunter